Baxter has launched ready-to-use Vancomycin Injection in 0.9% Sodium Chloride (Normal Saline) in 500mg, 750mg and 1g presentations. 

RELATED: AKI Incidence Compared in Vancomycin Combo Therapies

The launch is an extension of Baxter’s existing Vancomycin injection in 5% dextrose in 500mg, 750mg and 1g presentations and provides an alternative to certain patients who may need to avoid receiving additional dextrose. 

Vancomycin Injection, a tricyclic glycopeptide antibiotic, is indicated for the treatment of serious or severe infections due to susceptible methicillin-resistant (beta-lactam-resistant) staphylococci in penicillin-allergic patients; patients who cannot receive or have failed to respond to other drugs, including penicillins and cephalosporins; and for infections due to vancomycin-susceptible organisms resistant to other antimicrobials. 

It is also used to treat Staphylococcal endocarditis, including septicemia, and infections of the lower respiratory tract, bone, and skin and skin structure; Streptococcal endocarditis due to Sviridans or S.bovis as monotherapy or in combination with an aminoglycoside; Enterococcal endocarditis due to E. faecalis in combination with an aminoglycoside; Diphtheroid endocarditis; early-onset prosthetic valve endocarditis due to Sepidermidisor diphtheroids in combination with rifampin, or an aminoglycoside, or both.

For more information call (224) 948-5353 or visit